{"nctId":"NCT00655551","briefTitle":"Safety of Intravenous Lacosamide Dose Followed by Twice Daily Oral Lacosamide in Subjects With Partial-onset Seizures","startDateStruct":{"date":"2008-04"},"conditions":["Partial Epilepsies","Partial Onset Seizures"],"count":100,"armGroups":[{"label":"Lacosamide 200 mg cohort","type":"EXPERIMENTAL","interventionNames":["Drug: lacosamide"]},{"label":"Lacosamide 300 mg combined cohorts","type":"EXPERIMENTAL","interventionNames":["Drug: lacosamide"]},{"label":"Lacosamide 400 mg cohort","type":"EXPERIMENTAL","interventionNames":["Drug: lacosamide"]}],"interventions":[{"name":"lacosamide","otherNames":["Vimpat"]},{"name":"lacosamide","otherNames":["Vimpat"]},{"name":"lacosamide","otherNames":["Vimpat"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Diagnosis of epilepsy with simple partial seizures and/or complex partial seizures\n* Stable dose regimen of 1 to 2 marketed antiepileptic drug(s) (AED(s)) for 28 days prior to screening and duration of trial\n* Acceptable candidate for venipuncture and intravenous (iv) infusion\n* At least 1 partial seizure with motor component per 90 days\n* Maximum allowed seizure frequency during 28 days prior to screening is 40 partial seizures of any type\n\nExclusion Criteria:\n\n* Previous use of lacosamide\n* History of primary generalized seizures\n* History of status epilepticus within last 12 months\n* History of cluster seizures during 8 week period prior to screening\n* Non-epileptic events, including psychogenic seizures that could be confused with seizures\n* Use of neuroleptics, monoamine oxidase (MAO) inhibitors, barbiturates, or narcotic analgesics within 28 days prior to screening\n* Received any rescue benzodiazepines more than once during the 28 days prior to screening\n* Concomitant treatment of felbamate or previous felbamate therapy within last 6 months\n* Prior or concomitant vigabatrin use","healthyVolunteers":false,"sex":"ALL","minimumAge":"16 Years","maximumAge":"60 Years","stdAges":["CHILD","ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Subjects With at Least One Adverse Event During the Treatment Period (up to 7 Days)","description":"An Adverse Event (AE) is any untoward medical occurrence (eg, noxious or pathological changes) in a subject or clinical investigation subject compared with pre-existing conditions, that occurs during any period of a clinical trial including Pre-treatment, Run-In, Wash-Out, or Follow-Up Periods. An AE is defined as being independent of assumption of any causality (eg, to study or concomitant medication, primary or concomitant disease, or study design).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"17","spread":null},{"groupId":"OG001","value":"42","spread":null},{"groupId":"OG002","value":"20","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Subjects Who Withdrew From the Trial Due to an Adverse Event","description":"An Adverse Event (AE) is any untoward medical occurrence (eg, noxious or pathological changes) in a subject or clinical investigation subject compared with pre-existing conditions, that occurs during any period of a clinical trial including Pre-treatment, Run-In, Wash-Out, or Follow-Up Periods. An AE is defined as being independent of assumption of any causality (eg, to study or concomitant medication, primary or concomitant disease, or study design).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"3","spread":null},{"groupId":"OG002","value":"4","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With at Least One Adverse Event With an Onset Within 4 Hours of Start of Infusion","description":"An Adverse Event (AE) is any untoward medical occurrence (eg, noxious or pathological changes) in a subject or clinical investigation subject compared with pre-existing conditions, that occurs during any period of a clinical trial including Pre-treatment, Run-In, Wash-Out, or Follow-Up Periods. An AE is defined as being independent of assumption of any causality (eg, to study or concomitant medication, primary or concomitant disease, or study design).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"24","spread":null},{"groupId":"OG002","value":"16","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":25},"commonTop":["Dizziness","Somnolence","Nausea","Fatigue","Diplopia"]}}}